Elevar Therapeutics
Korea - SeoulBiotechnology
Focus: Elevar Therapeutics is a Seoul-based oncology-focused biotech founded in 2024, with a pipeline of 11 clinical programs spanning Phase 1–3 development across solid tumors and rare cancers. The company has achieved its first FDA approval (Lirafugratinib/Lyrfigtu) and is actively scaling commercial and operational functions.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Open Jobs
8+2 this month
Stable — net +2 jobs in 30d
4 added, 2 removed. Backfill posture.
Should You Work at Elevar Therapeutics?
AI assessmentElevar is a nascent oncology biotech with regulatory momentum but high early-stage risk; ideal for risk-tolerant professionals seeking hands-on roles in a commercializing company with emerging pipeline depth.
Why Work Here
- Early-stage biotech with demonstrated regulatory success: achieved FDA approval for Lirafugratinib in cholangiocarcinoma (Sept 2026) and EMA marketing authorization submission, validating drug development approach.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Apatinib
Advanced MalignanciesClinical Trials (1)
NCT03407976Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
Phase 1Help build intelligence for Elevar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.